Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High – What’s Next?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s share price hit a new 52-week high during trading on Thursday. The stock traded as high as $82.98 and last traded at $80.8850, with a volume of 226,231 shares trading hands. The stock had previously closed at $78.84.

Analysts Set New Price Targets

A number of analysts recently commented on KNSA shares. Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals International in a research report on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 target price for the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, Canaccord Genuity Group upped their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average price target of $93.14.

Kiniksa Pharmaceuticals International Trading Up 1.8%

The company has a market capitalization of $6.26 billion, a PE ratio of 82.73 and a beta of 0.04. The firm has a fifty day moving average of $77.75 and a two-hundred day moving average of $63.60.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. The company had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Insider Activity

In other news, CAO Michael R. Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 51.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the company. Inspire Investing LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth $1,698,000. Headlands Technologies LLC bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth $1,161,000. OMERS ADMINISTRATION Corp bought a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $631,000. SG Americas Securities LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 18.2% in the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after purchasing an additional 98,783 shares during the last quarter. Finally, Handelsbanken Fonder AB purchased a new position in Kiniksa Pharmaceuticals International during the second quarter worth $1,343,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company’s strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa’s primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older.